Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD31/PECAM‑1 is a key adhesion molecule highly expressed on tumor-associated endothelial cells. It plays central roles in angiogenesis, regulation of vascular permeability/barrier function during vessel remodeling, and control over immune cell trafficking into tissues—including tumors. Its expression makes it both a valuable biomarker for assessing tumor vasculature status and an attractive therapeutic target for strategies aimed at disrupting pathological angiogenesis or improving drug delivery within solid malignancies.
Antiangiogenic therapies; Enhancing drug delivery; Modulation of immune infiltration
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet Endothelial Cell Adhesion Molecule‑1 (PECAM-1).